ArticleActa neurologica Belgica2026
Neurofilament light chain levels as a biomarker in idiopathic intracranial hypertension: correlations with papilledema and radiological findings.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serum and CSF neurofilament light chain and glial fibrillary acidic protein levels in idiopathic intracranial hypertension.The journal of headache and pain · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic intracranial hypertension (IIH) is marked by elevated intracranial pressure with risk of vision loss. Neurofilament light chain (NfL), a marker of axonal injury, may reflect optic nerve damage in IIH.
objectiveTo assess the relationship between cerebrospinal fluid (CSF) and serum NfL levels, papilledema severity, and radiological findings in patients with IIH.
methodsA cross-sectional study was performed on 34 women with IIH and 34 age- and sex-matched healthy controls. Demographics, clinical features, ophthalmological evaluation, lumbar puncture opening pressure measurement, brain MRI/MRV, and ONSD ultrasound were performed. NfL levels were measured in CSF and serum using ELISA. Correlations with papilledema grade (Frisén scale) and radiological findings were analyzed.
resultsIIH patients had higher BMI (34.2 vs. 27.3 kg/m², p < 0.001) and ONSD (6.39 vs. 5.40 mm, p < 0.001). CSF NfL levels were elevated (median 79.8 ng/L) and positively correlated with papilledema grade (r = 0.383, p = 0.031) but negatively with ONSD (r = -0.352, p = 0.041). ONSD correlated strongly with papilledema (r = 0.456, p = 0.009) and lumbar puncture pressure (r = 0.502, p = 0.002). Serum NfL showed no significant difference between patients and controls (p = 0.562) and no correlation with disease severity.
conclusionCSF NfL correlates with papilledema grade and may serve as an objective biomarker of optic nerve damage in IIH. Its complementary role alongside ONSD suggests potential for a dual biomarker approach, combining acute pressure assessment with cumulative axonal injury monitoring.
Indexed as
Identifiers
41264200What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.